Tag: Humira

August 15, 2019

10 Top Drug Sales to Watch Until 2024

Drug sales are expected to top US$1 trillion by 2024, even though a number of patents are set to expire...
January 25, 2019

Coherus BioSciences Announces Global Settlement with AbbVie

Coherus BioSciences (Nasdaq:CHRS), a commercial biosimilar company, announced it has executed settlement agreements with AbbVie that grant Coherus global, non-exclusive...
April 30, 2018

8 Glioblastoma Treatment Stocks

With an average survival rate of 16 months, glioblastoma is the most common and deadly type of brain cancer, accounting...
February 21, 2018

Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update

Momenta Pharmaceuticals (Nasdaq:MNTA) today reported its financial results for the fourth quarter and year ended December 31, 2017 and provided a...
February 8, 2018

Everthing You Need to Know About the Longevity Thematic ETF

In the last year, LNGR has given investors a 23.67 percent return, and is expected to increase by 29.38 percent...
January 16, 2017

3 Blockbuster Drugs that Changed the Market

These three blockbuster drugs transformed pharmaceutical investing. But will we ever see anything like them again?
January 10, 2017

Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis

Coherus BioSciences, Inc. (NASDAQ:CHRS), today reported results from an ongoing 3-Part, Phase 3 clinical study of CHS-1420, an adalimumab (HUMIRA)...